Jasper Therapeutics
REDWOOD CITY, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that updated data from the Companys ongoing study of JSP191 as single agent conditioning prior to allogeneic hematopoietic stem cell (HSC) re-transplant in patients with severe combined immunodeficiency (SCID) has been accepted for presentation as a late-breaking poster at the 2022 Clinical Immunology Society (CIS) Annual Meeting, to be held in Charlotte, North Carolina from March 31 to April 3, 2022.
Title: Update: Single-Agent Conditioning with Anti-CD117 Antibody JSP191 Shows Donor Engraftment, Nave Lymphocyte Production, and Clinical Benefit in Patients with Severe Combined Immunodeficiency (SCID)Date and Time: Friday, April 1, 2022, 1:00-2:00 p.m. ET
This updated data indicates that JSP191 at 0.6mg/kg can deplete blood stem cells, leading to long-term donor cell engraftment, immune reconstitution which positively affects the clinical status of SCID patients who suffer from poor T cell and negligible B cell immunity because they failed their first transplant, said Wendy Pang, MD, Ph.D., Senior Vice President of Research and Translational Medicine of Jasper Therapeutics. This population of SCID patients is largely without treatment options and rely on supportive therapies like life long IVIG to provide some level of immune protection. JSP191 based conditioning may provide these patients with the best chance of a safe and successful transplant and reconstituted immune system.
CIS attendees are the primary caregivers for the immune deficient patient population, we are pleased to be able to present this data at the 2022 CIS annual meeting, Ronald Martell, CEO of Jasper. We believe that with our successful clinical efforts, we are one step closer, and uniquely positioned to deliver a targeted non-genotoxic conditioning agent to patients with SCID.
Story continues
About JSP191
JSP191 is a humanized monoclonal antibody in clinical development as a conditioning agent that blocks stem cell factor receptor signaling leading to clearance of hematopoietic stem cells from bone marrow, creating an empty space for donor or genetically modified transplanted stem cells to engraft. To date, JSP191 has been evaluated in more than 100 healthy volunteers and patients. Three clinical trials for myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML), severe combined immunodeficiency (SCID) and Fanconi anemia are currently enrolling. The Company plans a new study of JSP191 as a second-line therapeutic in lower risk MDS patients in 2022 as well as to a pivotal study in MDS/AML transplant in early 2023. Enrollment in additional studies are planned in patients with sickle cell disease, chronic granulomatous disease and GATA2 MDS who are undergoing hematopoietic cell transplantation.
About Jasper Therapeutics
Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, an anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing hematopoietic cell transplantation. It is designed to enable safer and more effective curative allogeneic hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing its preclinical mRNA engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.
Forward-Looking Statements
Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as believe, may, will, estimate, continue, anticipate, intend, expect, should, would, plan, predict, potential, seem, seek, future, outlook and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the potential long-term benefits of hematopoietic stem cells (HSC) engraftment following targeted single-agent JSP191 conditioning in the treatment of severe combined immunodeficiency (SCID) and Jaspers ability to potentially deliver a targeted non-genotoxic conditioning agent to patients with SCID. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Jaspers product candidates; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that Jaspers product candidates may not be beneficial to patients or successfully commercialized; patients willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jaspers business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jaspers business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics, including the ongoing COVID-19 pandemic; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jaspers filings with the SEC. If any of these risks materialize or Jaspers assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jaspers assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Contacts:John Mullaly (investors)LifeSci Advisors617-429-3548jmullaly@lifesciadvisors.com
Jeet Mahal (investors)Jasper Therapeutics650-549-1403jmahal@jaspertherapeutics.com
- Israeli-Based 3D-Printed Lab-Grown Meat Company is Building World's ... - December 27th, 2022
- Scientists Discover Protein Partners that Could Heal Heart Muscle | Newsroom - UNC Health and UNC School of Medicine - October 13th, 2022
- Global Synthetic Stem Cells Market Is Expected To Reach Around USD 42 Million By 2025 - openPR - October 13th, 2022
- A Look Into the Next Century After 100 Years of Insulin - Cureus - October 13th, 2022
- Grafting and Budding Nursery Crop Plants - North Carolina State University - October 4th, 2022
- Lifting up NC Teachers of the Year and TFA alumni - EdNC - August 22nd, 2022
- Vegan Oysters in Shells? This Startup Just Developed a Prototype to Save the Oceans - VegNews - July 27th, 2022
- How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety and more - KYMA - July 19th, 2022
- Inceptor Bio Announces Strategic Collaboration with University of Minnesota to Develop Novel iPSC Platform for the Advancement of Next-Generation... - July 3rd, 2022
- W-S organization working on regenerative therapies for 40 organs, tissues - WRAL TechWire - July 3rd, 2022
- BioRestorative Therapies Annou - GuruFocus.com - July 3rd, 2022
- How psilocybin, the psychedelic in mushrooms, may rewire the brain to ease depression, anxiety - WYFF4 Greenville - June 13th, 2022
- Pediatric Urologist Dr. Anthony Atala to Receive 2022 Jacobson Innovation Award of the American College of Surgeons for Pioneering Work in... - June 13th, 2022
- The Soybean Plant | NC State Extension Publications - June 4th, 2022
- A Cure for Type 1 Diabetes? For One Man, It Seems to Have Worked. - June 4th, 2022
- Hoth Therapeutics Announces a Sponsored Research Agreement to Further Develop Novel mRNA Cancer Therapeutic HT-KIT - Yahoo Finance - November 22nd, 2021
- Cytovia and Cellectis Expand Their TALEN Gene-Edited iNK Partnership to Enable Broader ... - The Bakersfield Californian - November 22nd, 2021
- Study Underway to Evaluate New PD-1/CD3 Antibody in T-cell Lymphoma - Targeted Oncology - October 28th, 2021
- What it means to be the worlds first IVF baby - THE WEEK - August 31st, 2021
- Cellectis Announces Participation in Five Investor Conferences - Yahoo Finance - August 31st, 2021
- Nanodecoy Therapy is an Effective Alternative to Neutralize SARS-CoV-2 Virus - AZoNano - June 23rd, 2021
- 'Nanodecoy' Therapy Binds and Neutralizes SARS-CoV-2 Virus - NC State News - June 23rd, 2021
- Researchers curb local immune response in horses receiving stem cell injury therapy - Horsetalk - February 7th, 2021
- After Bone Marrow Donation Saves 9-Year-Old Boy With Cancer, Boston Mom Fights To Raise Awareness - Here And Now - February 7th, 2021
- Invisible pest causes more than $1 billion in crop losses - The Albany Herald - January 13th, 2021
- Bayer to acquire Asklepios Bio in foray into gene therapy worth up to $4 billion - Reuters - January 13th, 2021
- Chancellor Harold L. Martin, on His Plan to Safely Open the Nation's Largest HCBU During COVID-19 - TIME - August 23rd, 2020
- Inside the race to ditch formula and grow breast milk in the lab - Wired.co.uk - August 23rd, 2020
- Study finds little evidence to back cord-blood therapy for autism - Spectrum - June 12th, 2020
- Balding men could grow hair back in weeks thanks to 'miracle potion' - Daily Star - May 19th, 2020
- Treatment in clinical trial offers options to woman fighting return of cancer (+ video) - WRAL Tech Wire - February 28th, 2020
- Searching for the 'big break' that could turn stem cells into a weapon against dementia - Genetic Literacy Project - February 28th, 2020
- Why Some COVID-19 Cases Are Worse than Others - The Scientist - February 28th, 2020
- The Future of Bioprinting Research Has a New Road Map - 3DPrint.com - February 14th, 2020
- Top Florida Medical Spa, Amnion of Florida, Partners With Merakris Therapeutics to Advance Their Non-Surgical Treatment Options - Business Wire - December 11th, 2019
- Synthetic Stem Cells Market Is Expecting Revolutionary Growth 2019 with Top Key Players: North Carolina State University (NCSU), Zhengzhou University... - December 6th, 2019
- Clinic pitches unproven treatments to desperate patients, with tips on raising the cash - Seattle Times - December 6th, 2019
- Reviewing vTv Therapeutics Inc. (VTVT)'s and Asterias Biotherapeutics Inc. (:)'s results - MS Wkly - October 27th, 2019
- Reviewing BioCryst Pharmaceuticals Inc. (BCRX)'s and Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)'s results - MS Wkly - October 27th, 2019
- Global Synthetic Stem Cells Market Estimated to Reach USD 42 Million By 2025 - Daily Market Updates - September 29th, 2019
- Global Synthetic Stem Cells Market to Accumulate Revenues Worth US $42 Million By 2025 - ZMR News Research - September 24th, 2019
- Heal Yourself: How Exosome Therapy Can Repair Age-Damaged Skin - Market Research Finance - September 24th, 2019
- Cesca Therapeutics Inc. (KOOL) Can't Be More Safe. Trades Significantly Higher - Invest Tribune - September 24th, 2019
- Stem Cell Winston Salem North Carolina 27150 - April 5th, 2019
- Clinical Trial for Autism - cordbloodbank.com - March 8th, 2019
- Stem Cell Chapel Hill North Carolina 27514 - February 11th, 2019
- Alumna to compete for Miss America crown on Sunday - UNCSA - February 3rd, 2019
- Stem Cell Therapy Latest Research Charlotte, North Carolina - December 2nd, 2018
- Stem Cell Therapy North Carolina | Regenerative Medicine ... - October 4th, 2018
- Bone Marrow Transplant | Durham, Raleigh, North Carolina ... - July 24th, 2018
- Charlotte, North Carolina - Stem Cells Transplant Institute - July 15th, 2018
- Stem Cell Greensboro North Carolina 27455 - July 15th, 2018
- Spotlights Archive | The University of North Carolina at ... - October 15th, 2017
- Stem Cells in Focus - Blog - Closer Look at Stem Cells - October 10th, 2017
- Avalon Advisors Has Decreased Its Comcast Cmn Class (CMCSA) Position; Neuralstem (CUR)'s Sentiment Is 0 - High Point Observer - September 6th, 2017
- Former basketball star Greg Friel in fight of his life - Fosters - Foster's Daily Democrat - August 15th, 2017
- Lung fibrosis? Stem cell therapy holds promise - The Hindu - The Hindu - August 11th, 2017
- Stem cells may treat lung fibrosis diseases - Futurity: Research News - August 11th, 2017
- CRISPR Edits Genome of Human Embryos - Alzforum - August 11th, 2017
- Cary NC Stem Cell Treatment | Cary North Carolina Cancer ... - November 16th, 2016
- Cato - Research Triangle Park, Durham, North Carolina - August 21st, 2016
- Biotechnology Teacher Resources Online | North Carolina ... - August 19th, 2016
- Stem Cell Research in North Carolina ... Whats Really ... - August 5th, 2016
- JCI - Type 2 alveolar cells are stem cells in adult lung - October 19th, 2015
- Cary North Carolina Stem Cell Research | Cary NC Stem Cell ... - July 2nd, 2015
- Core labs | North Carolina Biotech Center - April 29th, 2015
- Image: Human endothelial cells experiment bound for ISS - February 26th, 2015
- COPD Prognosis Stem Cells Canada, COPD Alternative ... - February 17th, 2015
- Cancer Care Northwest Stem Cell Transplantation - January 10th, 2015
- Dying child approved for new treatment testing - January 2nd, 2015
- New e-Incubator enables real-time imaging of bioengineered tissues in controlled unit - November 5th, 2014
- Committee on Development, Regeneration, and Stem Cell ... - October 31st, 2014
- Local doctor uses stem cells to heal - October 29th, 2014
- Study Offers Fertility Preservation Option to Young Boys with Cancer - October 1st, 2014
- Fayetteville North Carolina Stem Cell Research ... - September 16th, 2014
- Charlotte NC Resources - Stem Cells: Get Facts on Uses ... - September 1st, 2014
- For the first time, researchers isolate adult stem cells ... - August 26th, 2014
- The Man Who Grew Eyes From Scratch - August 26th, 2014
- Carolina Stem Cell Treatment Center | carolina stem ... - August 22nd, 2014
- North Carolina Stem Cell Treatment | Stem Cell Treatments - August 22nd, 2014